Protocol for a systematic review and network meta-analysis of second-line soft tissue sarcoma treatments
Protocol outlines options for second-line soft tissue sarcoma treatments
This is a protocol for a systematic review and network meta-analysis. It will evaluate second-line pharmacological regimens for advanced sof…
A new protocol maps second-line drug choices for advanced soft tissue sarcoma patients previously treated with anthracyclines, noting curren…
Post-hoc analysis suggests regional hyperthermia plus chemotherapy may improve survival in extremity soft tissue sarcoma
Adding heat to chemo may improve survival for soft-tissue sarcoma patients
This post-hoc analysis of a randomized trial examined overall survival in patients with extremity soft tissue sarcoma receiving neoadjuvant …
A post-hoc analysis of a randomized trial suggests adding regional hyperthermia to chemotherapy improved survival for patients with extremit…
mGPS associated with survival in advanced soft tissue sarcoma patients receiving trabectedin treatment in retrospective analysis
Blood Work May Predict Who Benefits From Sarcoma Drug
This retrospective cohort study evaluated 60 patients with advanced soft tissue sarcoma treated with trabectedin across multiple tertiary on…
A simple blood test score could help doctors predict how long patients live after starting a specific sarcoma treatment.
Retrospective cohort study assesses delta-NLR and baseline NLR for prognosis in soft tissue sarcoma
A Simple Blood Test Change Could Predict Survival in Sarcoma
This retrospective cohort study included 231 patients with soft tissue sarcoma.
Watching how a blood marker changes during treatment may give sarcoma patients a clearer picture of their future.
Research across Epithelioid Sarcoma
Related studies from across the Epithelioid Sarcoma family.
Interval-compressed VDC/IE protocol feasibility and outcomes in 27 Ewing's sarcoma patients at a North African center
Compressed chemotherapy showed mixed results for Ewing's sarcoma patients in a small study.
This retrospective, single-institutional cohort study evaluated an interval-compressed VDC/IE protocol in 27 patients with Ewing's sarcoma t…
A small study found that a compressed chemotherapy regimen for Ewing's sarcoma had high toxicity and low survival rates.
FDA Approves Pomalyst (pomalidomide) for Multiple Myeloma and Kaposi Sarcoma
FDA approves new drug Pomalyst for multiple myeloma and Kaposi sarcoma.
The FDA approved Pomalyst (pomalidomide) for multiple myeloma in combination with dexamethasone after at least two prior therapies, and for …
The FDA approved Pomalyst (pomalidomide) for two conditions: multiple myeloma and Kaposi sarcoma. It offers a new option for patients who ha…
Case report finds West Nile virus encephalitis in immunocompromised child after transfusions
Case report links West Nile virus infection to blood transfusions in Saudi Arabia
A case report with cross-sectional donor screening describes a 4-year-old Saudi girl with Ewing's sarcoma who developed WNV encephalitis aft…
A 4-year-old Saudi girl with cancer developed a serious brain infection after receiving blood transfusions, highlighting risks for vulnerabl…
Case report describes diagnostic challenges in bilateral epithelioid sarcoma of the thigh
Imaging tests missed rare cancer in woman with thigh tumors, case report shows
A case report and literature review describes a 47-year-old woman with bilateral thigh masses where ultrasonography and MRI failed to provid…
Common scans missed a rare cancer in a woman with thigh tumors, proving that biopsies are vital when imaging results are unclear.
Questions about soft tissue sarcoma
What do researchers expect to find about second-line drugs for advanced soft tissue sarcoma?
Researchers expect to find that second-line drugs like trabectedin, pazopanib, and eribulin offer options after anthracycline failure, but consistent guidelines are still lacking due to the rarity of these cancers and diverse tumor types.
Full answer →Does a high delta-NLR predict a worse prognosis for soft tissue sarcoma patients?
A high delta-NLR, which measures the rise in neutrophil-to-lymphocyte ratio during treatment, predicts a worse prognosis for soft tissue sarcoma patients compared to those whose levels decrease.
Full answer →What second-line treatments are being reviewed for advanced soft tissue sarcoma after anthracycline?
After anthracycline failure, trabectedin and eribulin are standard second-line options, while pazopanib is also approved in some regions. Newer agents like repotrectinib are being studied for specific subtypes.
Full answer →Can regional hyperthermia plus chemotherapy improve survival for extremity soft tissue sarcoma?
Yes, adding regional hyperthermia to chemotherapy may improve survival for extremity soft tissue sarcoma, based on a post-hoc analysis of a randomized trial.
Full answer →